Last reviewed · How we verify
JAKi
At a glance
| Generic name | JAKi |
|---|---|
| Also known as | Tofacitinib, Upadacitinib, Baricitinib |
| Sponsor | Marie Hudson, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (PHASE3)
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (PHASE2)
- Effect of JAK Inhibitor on Erosion Healing in RA (PHASE4)
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JAKi CI brief — competitive landscape report
- JAKi updates RSS · CI watch RSS
- Marie Hudson, MD portfolio CI